Incyte Corporation (INCY) Stock: Falling Apart On Failed Clinical Trial

Incyte Corporation (NASDAQ: INCY) is falling apart in the market today after announcing that a Phase 3 clinical trial, in collaboration with Merck & Co., Inc. (NYSE: MRK) has ended with less-than-positive data. Of course, this struck fear in the minds of investors, sending the stock tumbling down. Today, we’ll talk about:   The clinical results; what we’re … Read more

Incyte Corporation (INCY) Stock: Takes A Dive As FDA Fails To Approve Treatment

Incyte Corporation (NASDAQ: INCY) is having an incredibly rough day in the market this morning, and for good reason. A treatment that was expected to be approved by the FDA was rejected, causing investor fears and leading to declines in the stock and prompting our partners at Trade Ideas to alert us to the movement. … Read more

Agenus (AGEN) Stock: Gaining On Amended Agreement With Incyte (INCY)

Agenus Inc (NASDAQ: AGEN) | Incyte Corporation (NASDAQ: INCY) Agenus is having an incredibly strong day in the market today. When the trading session started for the day, the stock was already trading well into the green. From there, the stock dipped a bit before a strong continuation of gains was seen in the chart. … Read more

Biotech Stock News (BCRX) (INCY)

BioCryst Pharmaceuticals (NASDAQ: BCRX) On February 8, 2016 shares of BioCryst Pharmaceuticals fell by more than 71% after the company had announced that it had failed a phase 2 trial. The phase 2 trial known as the OPuS-2 trial recruited a total of 108 patients with Hereditary Angiodema — HAE. HAE is a rare genetic … Read more